文献速递前列腺癌

18F-PSMA-1007 PET/CT 在前列腺癌生化复发且 PSA≤2.0 ng/ml 患者中的诊断效能

Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2019-11-28

该前瞻性研究纳入 40 例根治性治疗后低水平升高 PSA(0.008 至 ≤2.0 ng/ml)的前列腺癌患者,行 18F-PSMA-1007 PET/CT 并随访验证。总体检出率 60%,且随 PSA 水平升高而增加;验证病灶的灵敏度、特异度、PPV 和 NPV 分别为 100%、94.4%、66.7% 和 100%。

要点

  • 18F-PSMA-1007 PET/CT 在根治后低水平升高 PSA 患者中总体检出率为 60%。
  • PSA<0.5、0.5 至<1.0、1.0 至≤2.0 ng/ml 的检出率分别为 39%、55%、100%。
  • 验证病灶的灵敏度 100%、特异度 94.4%、PPV 66.7%、NPV 100%。

核心结论

  • 18F-PSMA-1007 PET/CT 在根治性治疗后低水平升高 PSA 的前列腺癌患者中检出率较高,且检出率依赖 PSA 水平。
  • 该显像亦表现出优良的灵敏度、特异度和阴性预测值。

研究设计与样本

  • 前瞻性纳入 40 例根治性治疗(80% 根治性前列腺切除,20% 放射束治疗)后低水平(0.008 至 ≤2.0 ng/ml)升高 PSA 的前列腺癌患者。
  • 注射 295.5(±14.1)MBq 18F-PSMA-1007 后 95(±12)分钟行颅顶至大腿中段 PET/CT 显像。
  • PET/CT 结果经 10.3(±4.7)个月随访验证,计算灵敏度、特异度、NPV 和 PPV。

主要发现

  • 18F-PSMA-1007 PET/CT 在 24/40 例患者中阳性,总体检出率 60%。
  • PSA<0.5、0.5 至<1.0、1.0 至≤2.0 ng/ml 的检出率分别为 39%、55%、100%。
  • PET/CT 显示区域淋巴结转移占 55%、骨转移占 36%、局部复发占 9%。
  • PSA 每升高 0.1 ng/ml,PET/CT 阳性几率增加约 30%;PET/CT 阳性与 GS 和 T 分期无关。
  • 验证 40 个病灶的灵敏度、特异度、PPV 和 NPV 分别为 100%、94.4%、66.7% 和 100%。

临床怎么用

  • 对于根治性治疗后低水平升高 PSA 的前列腺癌患者,可考虑使用 18F-PSMA-1007 PET/CT 进行生化复发定位。
  • 检出率随 PSA 水平升高而增加,临床解读时应结合 PSA 水平。

局限性

  • 样本量较小(40 例),随访时间较短(10.3±4.7 个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The aim of the study was to prospectively evaluate diagnostic performance of 18F-PSMA-1007 PET/CT in patients with prostate cancer (PCa) after radical treatment and low but rising prostate-specific antigen (PSA) levels. METHODS: We prospectively enrolled 40 consecutive patients after radical treatment (80%-radical prostatectomy, 20%-radiation beam therapy) of PCa and low (0.008 to ≤2.0 ng/ml), rising PSA. Skull to mid-thigh PET/CT imaging was performed 95 (±12) min after injection of 295.5 (±14.1) MBq 18F-PSMA-1007. Detection rate was correlated with PSA levels, Gleason score (GS) and T stage ≥ 3. PET/CT results were verified during 10.3 (±4.7) months follow-up to calculate sensitivity, specificity, negative predictive values (NPV) and positive predictive values (PPV). RESULTS: 18F-PSMA-1007 PET/CT was positive in 24/40 patients, which yielded overall detection rate of 60%. Detection rate was 39%, 55% and 100% for PSA < 0.5, 0.5 to <1.0 and 1.0 to ≤2.0 ng/ml, respectively. PET/CT showed metastases in locoregional lymph nodes in 55% of patients, bones in 36% of patients and local recurrence in 9% of patients. Detection rate was correlated with PSA-a 0.1 ng/ml rise in PSA level increased odds for positive PET/CT by ~30%. PET/CT positivity was independent of GS and T stage. Verification of 40 lesions yielded sensitivity, specificity, PPV and NPV of 100%, 94.4%, 66.7% and 100%, respectively. CONCLUSIONS: 18F-PSMA-1007 PET/CT shows relatively high detection rate in patients with PCa after radical treatment and low, rising PSA levels. Like other PSMA-targeting radiotracers, its detection rate is dependent on PSA levels. 18F-PSMA-1007 also presents excellent sensitivity, specificity and NPV.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Witkowska-Patena E, Giżewska A, Dziuk M, et al. Diagnostic performance of 18F-PSMA-1007 PET/CT in biochemically relapsed patients with prostate cancer with PSA levels ≤ 2.0 ng/ml. Prostate Cancer Prostatic Dis. 2019. PMID: 31780781. doi:10.1038/s41391-019-0194-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。